Other substances

Narsoplimab

A lectin pathway antibody inhibitor.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
1
 Clinical trials

General information

Narsoplimab is a fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody against MASP-2 (Rambaldi et al., 2020).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab
ARDS Case series Antibody 		Patients 2.79

Reduced markers of inflammation and endothelial damage in COVID-19 patients, with all treated patients recovering. Sample size: 6. Dosage: 4u202fmg/kg IV twice weekly for 2-4 weeks.

 Aug/09/2020

AI-suggested references

Link Publication date
Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins
Jul/15/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04488081 I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients Recruiting Phase 2 Jul/31/2020 Nov/01/2022
  • Alternative id - I-SPY-COVID
  • Interventions - Drug: Remdesivir|Drug: Pulmozyme|Drug: IC14|Drug: Celecoxib Famotidine|Drug: Narsoplimab|Drug: Aviptadil Acetate|Drug: Cyclosporine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of Alabama at Birmingham, Birmingham, Alabama, United States|UC Davis Medical Center, Davis, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|University of Southern California, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|University of California San Francisco (UCSF), San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montefiore Medical Center, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|University of Pennsylvania (U Penn), Philadelphia, Pennsylvania, United States|Main Line Health - Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Sanford Health, Sioux Falls, South Dakota, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 1500
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Identify agents that will result in substantial improvements to the clinical condition of participants with COVID-19|Improvement in disease severity|Health care utilization|Frequency of serious AEs|Mortality
Export (.csv)